Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-adMSCs for Chronic Post-COVID-19 Syndrome
NCT05126563Phase 2Completed
- Sponsor
- Hope Biosciences
- Start
- Feb 2022
- Primary completion
- Apr 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Post COVID-19 Syndrome (PCS) comparing HB-adMSCs with Placebo (2 arms). Primary endpoints: Visual Analog Scale of Neurological Symptoms - Extreme Fatigue at 26 weeks, Visual Analog Scale of Neurological Symptoms - Brain Fog at 26 weeks and 6 more. Started Feb 2022; status: completed.
02
Drugs
allogeneic HB-adMSCs
03
Conditions
Post COVID-19 Syndrome (PCS)
Beyond the preview
Go deeper on NCT05126563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126563.